Invasive mechanical ventilation (IMV) is a type of life support that uses a machine to help a person breathe when they cannot do so on their own. IMV is often used for patients who have severe respiratory failure due to conditions such as acute respiratory distress syndrome (ARDS), pneumonia, or COVID-19.
IMV involves inserting a tube called an endotracheal tube (ETT) through the mouth or nose and into the windpipe (trachea). The ETT is connected to a ventilator, which is a machine that delivers oxygen-rich air into the lungs and removes carbon dioxide-rich air out of the lungs. The ventilator can also adjust the pressure, volume, and rate of the air delivered to match the patient’s needs.
IMV can be lifesaving, but it can also have serious complications, such as lung injury, infection, bleeding, or vocal cord damage.
Therefore, IMV requires careful monitoring and management by trained staff who follow strict protocols for initiation, maintenance, and weaning of the device. Some of the key factors that influence the outcomes of IMV include:
- The indication for IMV (e.g., hypoxemic vs. hypercapnic respiratory failure, COVID-19 vs. non-COVID-19)
- The mode of ventilation (e.g., volume-controlled vs. pressure-controlled, assist-control vs. pressure-support)
- The settings of ventilation (e.g., tidal volume, positive end-expiratory pressure, fraction of inspired oxygen)
- The duration of ventilation (e.g., short-term vs. long-term)
- The complications of ventilation (e.g., ventilator-associated pneumonia, barotrauma, ventilator-induced lung injury)
- The weaning of ventilation (e.g., spontaneous breathing trial, extubating readiness)
The optimal management of IMV may vary depending on the individual patient’s condition and the available resources. However, some general recommendations based on the current evidence are:
- Use IMV only when necessary and wean it as soon as possible.
- Use low tidal volume and high positive end-expiratory pressure to prevent lung injury.
- Use prone positioning and neuromuscular blockade for severe hypoxemia.
- Use corticosteroids and anticoagulants for COVID-19 patients.
- Use daily sedation interruption and spontaneous breathing trial to facilitate weaning.
- Use noninvasive ventilation or high-flow nasal cannula as alternatives to IMV when possible.
